Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Veracyte Inc (VCYT)

Veracyte Inc (VCYT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,086,312
  • Shares Outstanding, K 78,315
  • Annual Sales, $ 445,760 K
  • Annual Income, $ 24,140 K
  • EBIT $ 24 M
  • EBITDA $ 47 M
  • 60-Month Beta 2.10
  • Price/Sales 4.65
  • Price/Cash Flow 25.50
  • Price/Book 1.73

Options Overview Details

View History
  • Implied Volatility 73.27% ( +0.04%)
  • Historical Volatility 37.12%
  • IV Percentile 46%
  • IV Rank 53.95%
  • IV High 109.12% on 04/14/25
  • IV Low 31.27% on 07/05/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 26
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 1,239
  • Open Int (30-Day) 1,067

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 0.19
  • Number of Estimates 4
  • High Estimate 0.22
  • Low Estimate 0.15
  • Prior Year 0.30
  • Growth Rate Est. (year over year) -36.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.85 +3.52%
on 06/16/25
29.10 -8.04%
on 05/19/25
-2.44 (-8.36%)
since 05/16/25
3-Month
25.85 +3.52%
on 06/16/25
34.19 -21.73%
on 03/26/25
-4.47 (-14.31%)
since 03/17/25
52-Week
19.73 +35.63%
on 08/05/24
47.32 -43.44%
on 01/30/25
+5.38 (+25.16%)
since 06/17/24

Most Recent Stories

More News
Veracyte: Q1 Earnings Snapshot

Veracyte: Q1 Earnings Snapshot

VCYT : 26.76 (+0.45%)
Veracyte: Q4 Earnings Snapshot

Veracyte: Q4 Earnings Snapshot

VCYT : 26.76 (+0.45%)
Brian's Big Idea: Healthcare Stocks

One of the most difficult sectors to invest in is the healthcare sector. Not only do you have to be nuanced in the ways of the stock market but you also have to have a deep understanding of medicines,...

VCYT : 26.76 (+0.45%)
HIMS : 59.24 (-0.90%)
BBIO : 40.07 (-2.60%)
Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now

Bio-Rad Laboratories, Inc.’s BIO solid momentum in the QX600 Droplet Digital PCR (ddPCR) platform is poised to help it grow in the upcoming quarters. The clinical diagnostics business sees increased...

VCYT : 26.76 (+0.45%)
BIO : 230.46 (-0.54%)
PAHC : 24.45 (-1.05%)
HAE : 69.01 (-1.36%)
Should National Vision Stock Be in Your Portfolio Right Now?

National Vision Holdings, Inc. EYE is winning market shares across four sub segments of the Owned and Host. The company is also advancing its transformation efforts with continued expansion of exam capacity,...

VCYT : 26.76 (+0.45%)
EYE : 22.36 (+0.04%)
PAHC : 24.45 (-1.05%)
HAE : 69.01 (-1.36%)
Macroeconomic Woes, FX Headwind Drag NEOG Stock Down

Neogen's NEOG vast international trade is being impacted by global macroeconomic issues. Also, a tough competitive landscape weighs on the stock. NEOG stock carries a Zacks Rank #4 (Sell) currently.Factors...

VCYT : 26.76 (+0.45%)
PAHC : 24.45 (-1.05%)
NEOG : 5.28 (-6.38%)
HAE : 69.01 (-1.36%)
Henry Schein Stock to Gain From New Acquisitions Amid Macro Woes

Henry Schein HSIC is well positioned to gain from its extensive global foothold and diverse channel mix.  Yet, global economic uncertainties are concerns for Henry Schein. The stock carries a Zacks Rank...

VCYT : 26.76 (+0.45%)
HSIC : 70.16 (-0.85%)
PAHC : 24.45 (-1.05%)
HAE : 69.01 (-1.36%)
Here's Why You Should Add Ensign Group Stock to Your Portfolio Now

The Ensign Group, Inc. ENSG is benefiting from strategic acquisitions, an expanding footprint, rising service revenues and a strong financial position. An optimistic 2024 business outlook also reinforces...

VCYT : 26.76 (+0.45%)
EMBC : 9.84 (-1.99%)
CDNA : 19.52 (+2.36%)
ENSG : 153.85 (+0.80%)
3 Medical Instruments Industry Stocks to Buy on the GenAI Wave

Through 2024, advancements in AI and predictive analytics rapidly revolutionized the Medical Instruments industry, driving innovation in diagnostics, patient monitoring and personalized treatment. AI-powered...

VCYT : 26.76 (+0.45%)
PEN : 255.95 (-1.92%)
MASI : 159.32 (-1.98%)
Insider Sale: Chief Commercial Officer-CLIA of $VCYT (VCYT) Sells 1,050 Shares

John Leite, the Chief Commercial Officer-CLIA of $VCYT ($VCYT), sold 1,050 shares of the company on 12-03-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

VCYT : 26.76 (+0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also...

See More

Key Turning Points

3rd Resistance Point 28.03
2nd Resistance Point 27.43
1st Resistance Point 27.10
Last Price 26.76
1st Support Level 26.17
2nd Support Level 25.57
3rd Support Level 25.24

See More

52-Week High 47.32
Fibonacci 61.8% 36.78
Fibonacci 50% 33.52
Fibonacci 38.2% 30.27
Last Price 26.76
52-Week Low 19.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar